Xodol

hydrocodone /hy·dro·co·done/ (-ko´dōn) a semisynthetic opioid analgesic similar to but more active than codeine; used as the bitartrate salt or polistirex complex as an analgesic and antitussive.

hydrocodone [hi″dro-ko´dōn]

a semisynthetic opioid analgesic similar to but more active than codeine; used as the bitartrate salt or polistirex complex as an oral analgesic and antitussive. Continued use may cause addiction.

hydrocodone (hī´drōkō´dōn),

n a semisynthetic narcotic analgesic and antitussive with multiple actions similar to those of codeine. Hydrocodone is an ingredient in prescription analgesics and cough medicines.

hydrocodone bitartrate,

n brand name: Hycodan;
drug class: narcotic analgesic, controlled substance schedule III;
action: interacts with opioid receptor in the central nervous system to alter pain perception; acts directly on cough center in medulla to suppress cough;
uses: hyperactive and nonproductive cough; mild to moderate pain.

hydrocodone

a synthetic narcotic analgesic similar to but more active than codeine; the bitartrate is used as an antitussive.

hydrocodone

An opioid analgesic, antitussive, which also depresses respiration, used for cough and upper respiratory Sx of allergies or colds. See Opioid.

Mentioned in	?		References in periodicals archive	?		Medical browser	?		Full browser	?
amyloidosis Analgesics, Opioid antitussive dihydrocodeinone Histussin homatropine Hycodan Hycomine hydrocodone bitartrate hydrocodone bitartrate and acetaminophen hydrocodone bitartrate and aspirin hydrocodone bitartrate and ibuprofen Narcotics Norco pain intervention schedule III agent Tussionex Vicodan Vicodin	This decrease is primarily attributed to: a decrease in net sales for our Specialty Pharmaceuticals segment, largely due to a strategy shift resulting in the divestiture of our Xodol and Histex product lines in order to focus on products with higher growth potential; and to a lesser extent due to a decrease in net sales in Analytica and Biovest. ACCENTIA REPORTS FISCAL 2007 YEAR-END NET LOSS OF $76.0 MIL by Biotech Financial Reports 3 million in net sales in our Specialty Pharmaceuticals segment primarily due to the divestiture of our Xodol and Histex product lines, the discontinuance of our Respi-Tann G product line, product returns and, to a lesser extent, a decrease in net sales of our Analytica subsidiary. Accentia Biopharmaceuticals Reports Fiscal First Quarter 2008 ... by Business Wire This decrease is primarily attributed to: a decrease in net sales for our Specialty Pharmaceuticals segment, largely due to a strategy shift resulting in the divestiture of our Xodol and Histex product lines in order to focus on products with higher growth potential; and to a lesser extent due to a decrease in net sales in Analytica and Biovest. Accentia Biopharmaceuticals Reports Fiscal 2007 Year-End Results; ... by Business Wire	xerotic keratitis xerotomography xi Xi-cleft points Xifaxan Xigris Ximenia americana xin xiph(o)- xiph- xiphi- xiphisternal articulation xiphisternum xipho- xiphocostal xiphodynia xiphoid xiphoid process xiphoiditis xiphopagus Xiphophorus xixin XLD medium XO XO syndrome Xodol Xolair Xoloitzcuintli Xopenex XP XTC Xubix xue XX XX Male Syndrome XX sex reversal XX/XY chimaerism XXX XXX ovarian hypoplasia XXX Syndrome XXXX Syndrome XXXXX Syndrome XXXY XXXY males XXXY Syndrome XXY XXY syndrome XY XY gonadal agenesis syndrome XY sex reversal mares XY/XXY mosaic	XO ovarian dysgenesis XO syndrome XO syndrome XO system XOA XOAC XOAE xoana Xoanon XOATB XOB XOBIS XOC Xochicalco Xochimilco Xochimilco XOCM Xoco atl Xoco atl Xoco atl Xocoatl Xocoatl Xocoatl Xocolatl Xocolatl Xocolatl XOCOMM XOCP XoD Xodiac Network Bus Xodol XOF XOF Xoff Xoff XOG Xohm XOI XoIP XoIP XOJIG XOK XOL Xolair Xolegel Xolegel Xoloitzcuintle Club USA Xoloitzcuintli Xoloitzcuintli Club of America Xolotlan Xom XOML Xon Xon Xon-xoff XON/XOFF XOO

Mentioned in

References in periodicals archive

Medical browser

Full browser

amyloidosis
Analgesics, Opioid
antitussive
dihydrocodeinone
Histussin
homatropine
Hycodan
Hycomine
hydrocodone bitartrate
hydrocodone bitartrate and acetaminophen
hydrocodone bitartrate and aspirin
hydrocodone bitartrate and ibuprofen
Narcotics
Norco
pain intervention
schedule III agent
Tussionex
Vicodan
Vicodin

This decrease is primarily attributed to: a decrease in net sales for our Specialty Pharmaceuticals segment, largely due to a strategy shift resulting in the divestiture of our Xodol and Histex product lines in order to focus on products with higher growth potential; and to a lesser extent due to a decrease in net sales in Analytica and Biovest.

ACCENTIA REPORTS FISCAL 2007 YEAR-END NET LOSS OF $76.0 MIL by Biotech Financial Reports

3 million in net sales in our Specialty Pharmaceuticals segment primarily due to the divestiture of our Xodol and Histex product lines, the discontinuance of our Respi-Tann G product line, product returns and, to a lesser extent, a decrease in net sales of our Analytica subsidiary.

Accentia Biopharmaceuticals Reports Fiscal First Quarter 2008 ... by Business Wire

Accentia Biopharmaceuticals Reports Fiscal 2007 Year-End Results; ... by Business Wire

hydrocodone (redirected from Xodol)

hydrocodone
(redirected from Xodol)